Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240370 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,159
- Enrollment target
NCT00240370 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,159 participants.
The verdict
NCT00240370, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,159 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if type 2 diabetics who have inadequate glycemic control on metformin alone, have a similar, or not inferior, glycemic response when treated with the combination of muraglitazar and metformin compared to pioglitazone and metformin.
Interventions
- DRUG Muraglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,159 participants |
| Start Date | 2003-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240370
The ClinicalTrials.gov registry entry for NCT00240370 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Muraglitazar is the first listed.
NCT00240370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00240370 about?
NCT00240370 is a clinical study titled "A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics". The purpose of this study is to evaluate if type 2 diabetics who have inadequate glycemic control on metformin alone, have a similar, or not inferior, glycemic response when treated with the combination of muraglitazar and metformin compared to pioglitazone and metformin.
What is the current status of trial NCT00240370?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,159 participants. The study started on 2003-10.
What interventions are being tested in trial NCT00240370?
The interventions under investigation include: Muraglitazar (DRUG).
Who is sponsoring clinical trial NCT00240370?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.